von der Maase H - Search Results

1

Ultrasonically guided insertion of a peritoneo-gastric shunt in patients with malignant ascites.

Lorentzen T, Sengeløv L, Nolsøe CP, Khattar SC, Karstrup S, von der Maase H. Lorentzen T, et al. Among authors: von der maase h. Acta Radiol. 1995 Sep;36(5):481-4. Acta Radiol. 1995. PMID: 7640091

2

Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer.

Andersen LJ, Sengeløv L, Kamby C, von der Maase H. Andersen LJ, et al. Among authors: von der maase h. Acta Oncol. 1998;37(1):110-2. doi: 10.1080/028418698423276. Acta Oncol. 1998. PMID: 9572664 Clinical Trial. No abstract available.

3

Systemic mitomycin C as second-line treatment for metastatic urothelial cancer.

Sengeløv L, Nielsen OS, Kamby C, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. Acta Oncol. 1995;34(7):978-9. doi: 10.3109/02841869509127221. Acta Oncol. 1995. PMID: 7492397 Clinical Trial. No abstract available.

4

Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

Als AB, Sengelov L, Von Der Maase H. Als AB, et al. Among authors: von der maase h. Acta Oncol. 2008;47(1):110-9. doi: 10.1080/02841860701499382. Acta Oncol. 2008. PMID: 17851853

5

Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors.

Sengeløv L, Nielsen OS, Kamby C, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. Cancer. 1995 Nov 15;76(10):1797-803. doi: 10.1002/1097-0142(19951115)76:10<1797::aid-cncr2820761018>3.0.co;2-w. Cancer. 1995. PMID: 8625050 Clinical Trial.

6

Radiotherapy in bladder cancer.

Sengeløv L, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. Radiother Oncol. 1999 Jul;52(1):1-14. doi: 10.1016/s0167-8140(99)00090-0. Radiother Oncol. 1999. PMID: 10577680 Review.

7

Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years.

Sengeløv L, Kamby C, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. Eur Urol. 2001 Jun;39(6):634-42. doi: 10.1159/000052520. Eur Urol. 2001. PMID: 11464051

8

Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract.

Sengeløv L, Kamby C, Schou G, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. Cancer. 1994 Jul 1;74(1):123-33. doi: 10.1002/1097-0142(19940701)74:1<123::aid-cncr2820740121>3.0.co;2-t. Cancer. 1994. PMID: 8004569

9

Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma.

Sengeløv L, Kamby C, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. J Urol. 1996 Jan;155(1):111-4. J Urol. 1996. PMID: 7490804

10

A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium.

Geertsen PF, Sengeløv L, Larsen SK, von der Maase H. Geertsen PF, et al. Among authors: von der maase h. Eur J Cancer. 1993;29A(3):347-50. doi: 10.1016/0959-8049(93)90383-q. Eur J Cancer. 1993. PMID: 8398332 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters